GET DAILY SIGNALSWhy Is PDS Biotechnology Corporation (PDSB) Stock Down -6.03% Today?
Key Takeaways
- Shares of PDSB fell roughly 6% to about $1.09 in Thursday's session, down from a prior close of $1.16.
- Primary catalyst: Profit-taking after a sharp, data-driven rally earlier this week, as traders locked in gains following the October 21 surge in the stock.
- Secondary drivers: A 16.5-million-share resale registration creating supply overhang, along with analyst price-target reductions and financing concerns.
- Broader context: The move reflects the elevated volatility typical of small-cap, pre-revenue clinical-stage biotech names with tight balance sheets.
- What to watch next: The company's upcoming quarterly results and any further updates on its PDS0301 clinical program.
- Explore detailed Price Targets, Earnings, and Forecast pages for deeper analysis of this ticker.
- Discover top-performing automated strategies on the Trending AI Robots page.
Opening Summary
PDS Biotechnology Corporation (PDSB), a Princeton, New Jersey-based clinical-stage immunotherapy company developing targeted cancer treatments, saw its shares slide about 6.03% in Thursday's session. The stock traded near $1.09, down from the previous session's close of $1.16, as momentum reversed following a volatile week. The decline marked a continued give-back of the sharp gains the stock posted earlier in the week after the company highlighted positive clinical data for its lead immunotherapy candidate, with traders citing profit-taking, a sizable share-resale overhang, and lingering financing uncertainty as the immediate pressures on the stock.
Profit-Taking After a Data-Driven Rally
The most immediate driver behind Thursday's decline appears to be a classic "buy-the-rumor, sell-the-news" unwind. On October 21, shares of PDSB surged roughly 29% after the company presented encouraging Phase 2 data for PDS0301, its tumor-targeted IL-12 immunocytokine, in metastatic colorectal cancer with liver metastases. The data highlighted a 71.4% six-month objective response rate and a roughly 80% two-year survival rate in a National Cancer Institute-led study. The rally extended a broader rebound that had lifted the stock from below $0.80 earlier in the month. With those gains now in the books and no new incremental data immediately on the horizon, momentum traders and short-term investors moved to lock in profits, pressuring the stock over the past two sessions.
Share Resale Overhang Weighs on Sentiment
Compounding the pullback is a supply-side concern. Earlier in October, the company filed a registration statement covering the potential resale of up to 16.5 million existing shares by selling stockholders. While the registration does not involve the issuance of new shares—meaning it is not direct dilution—it creates a meaningful overhang by increasing the pool of stock that can legally hit the open market. For a micro-cap name with a limited float, that added potential supply has kept a lid on any recovery and contributed to the stock's inability to hold above the $1.10 level in recent sessions.
Financing Uncertainty and Analyst Revisions
Investors are also contending with the company's financial position. As a pre-revenue clinical-stage biotech, PDS Biotechnology depends on external capital to fund its pipeline, and its balance sheet remains tight. Analysts have trimmed their valuation expectations in recent weeks, with one prominent firm cutting its price target multiple times—from $15 to $7 and later to $5—while independent fair-value estimates moved lower as well. Recent commentary has cited funding needs, execution risk, and the structure of a Nant Capital-led financing as key uncertainties. That combination of a reduced valuation anchor and ongoing dilution risk has made the stock vulnerable to selling on any weakness.
Market Context and Trading Activity
The move in PDSB is consistent with the heightened volatility the stock has exhibited throughout October, when daily swings of 10% or more have been common. Volume during Thursday's decline was relatively moderate compared with the exceptionally heavy trading seen during the stock's earlier data-driven surges, suggesting the pullback was driven more by an absence of fresh buyers than by a rush of new sellers. The stock has slipped back toward the $1.10 area, a level market participants have been watching closely, with the psychologically significant $1.00 mark now in view on further downside. The decline also unfolded against a backdrop of generally cautious sentiment in speculative biotech, where capital-intensive names with near-term financing needs remain out of favor.
What Comes Next for PDSB
Looking ahead, the focus for PDSB shifts to its upcoming quarterly earnings report, currently estimated for mid-November, where investors will scrutinize cash runway and any updates on financing. The company has also signaled additional PDS0301 data readouts anticipated over the coming quarters across multiple indications, including prostate cancer and colorectal cancer with liver metastases, which could serve as the next meaningful catalysts. On the risk side, continued pressure on the balance sheet, the outstanding share-resale overhang, and the inherent uncertainty of clinical-stage development all remain central to the stock's outlook. Traders will be watching whether the stock can stabilize above key support levels or whether further declines toward $1.00 materialize.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots that have demonstrated strong performance under current market conditions. Tickeron offers hundreds of automated bots covering thousands of tickers, with strategies that vary by approach, timeframe, performance metrics, and traded symbols. Only the strongest performers are featured in this rotating selection, giving traders a way to explore systematic approaches across shifting market environments. Visit the page to see which strategies are currently leading.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PDSB's RSI Indicator leaves overbought zone
The 10-day RSI Oscillator for PDSB moved out of overbought territory on October 14, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 instances where the indicator moved out of the overbought zone. In 20 of the 22 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for PDSB turned negative on October 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 44 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PDSB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
PDSB broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on PDSB as a result. In 69 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The 10-day moving average for PDSB crossed bullishly above the 50-day moving average on September 18, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +35.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where PDSB advanced for three days, in 192 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Aroon Indicator entered an Uptrend today. In 79 of 107 cases where PDSB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 74%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-23.485) is normal, around the industry mean (2.973). P/E Ratio (-1.812) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Seasonality Score of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. PDSB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 93 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PDSB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of clinical-stage immunotherapies to treat various early-stage and late-stage cancers which includes head & neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer and related cancers
Industry Biotechnology
Advertisement